Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 11/20 | 0.53 |
| ▸ | MAOB | P27338 | 11/20 | 0.53 |
| ▸ | HPD | P32754 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14212063 | 0.86 | MAOA (0.64) | MAOAMAOBHPD | |
| SCHEMBL10314931 | 0.79 | GRM5 (0.48) | MAOAMAOBCYP11B2GRM5 | |
| SCHEMBL10314871 | 0.77 | GRM5 (0.53) | CYP11B2GRM5CYP1A2 | |
| SCHEMBL10286601 | 0.75 | CYP11B2 (0.37) | MAOAMAOBCYP11B2 | |
| SCHEMBL10314897 | 0.74 | HPD (0.53) | MAOAMAOBHPD | |
| SCHEMBL10314870 | 0.72 | GRM5 (0.56) | GRM5 | |
| SCHEMBL10009266 | 0.72 | GRM5 (0.56) | GRM5 | |
| SCHEMBL10314885 | 0.71 | GRM5 (0.44) | CYP11B2GRM5CYP1A2 | |
| SCHEMBL10271350 | 0.70 | MAOA (0.49) | MAOAMAOBCYP11B2 | |
| SCHEMBL226640 | 0.69 | MAOB (1.00) | MAOAMAOBGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853237-B2 | Naphthyridinone analogs as mGluR5 positive allosteric modulators | VANDERBILT UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| US-20120172391-A1 | NAPHTHYRIDINONE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172391-A1 | NAPHTHYRIDINONE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | GRM5, GRIK5, GRM1 | MAOA 3688/4885MAOB 3685/4885HPD 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.